Week of Apr. 16, 2012: Merck & Co., Endocyte Form Development Pact; West Pharma Adds to NovaPure Brand; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of Apr. 16, 2012: Merck & Co., Endocyte Form Development Pact; West Pharma Adds to NovaPure Brand; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Lonza and Agennix have signed a development and manufacturing contract for the production of talactoferrin, an oral dendritic cell-mediated immunotherapy to treat nonsmall-cell lung cancer. Under the agreement, Lonza will produce commercial material at its microbial manufacturing facility in Kouřim, Czech Republic. This agreement initiates the process for Lonza as a second manufacturer of talactoferrin after the initial commercial launch. Read More

Merck & Co. and Endocyte have agreed to develop and commercialize the Phase III cancer candidate vintafolide. Under the agreement, Merck, through a subsidiary, will gain worldwide rights to develop and commercialize vintafolide. Endocyte will receive a $120-million upfront payment and is eligible for milestone payments of up to $880 million based on the successful achievement of development, regulatory, and commercialization goals for vintafolide for a total of six cancer indications. If vintafolide receives regulatory approval. Endocyte has retained the right to copromote vintafolide with Merck in the US and Merck has the exclusive right to promote vintafolide in the rest of world. Endocyte will be responsible for the majority of funding and completion of the Proceed trial. Merck will be responsible for all other development activities and costs and have all decision rights for vintafolide. Endocyte remains responsible for the development, manufacture, and commercialization worldwide of etarfolatide, a noninvasive companion diagnostic imaging agent that is used to identify folate receptor positive tumor cells. Read More

West Pharmaceutical Services has introduced a new line of components under its NovaPure brand at the PDA Annual Meeting. Through a product development process that incorporates quality by design principles. The pure components, include serum and lyophilization stoppers and syringe plungers.

Industry Briefs:

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here